Elevated plasma aldosterone levels despite complete inhibition of the vascular angiotensin-converting enzyme in chronic heart failure

Circulation

Volumn 106, Issue 9, 2002, Pages 1055-1057

  Jorde, Ulrich P ^a   Vittorio, Timothy ^a   Katz, Stuart D ^a   Colombo, Paolo C ^a   Latif, Farhana ^a   Le Jemtel, Thierry H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Aldosterone; Angiotensin; Heart failure

Indexed keywords

ALDOSTERONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; FUROSEMIDE; LISINOPRIL; TRANDOLAPRIL;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CLINICAL ARTICLE; ENZYME INHIBITION; FEMALE; HEART FAILURE; HUMAN; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ALDOSTERONE; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CHRONIC DISEASE; ENZYME ACTIVATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; RADIAL ARTERY; SODIUM, DIETARY; TONOMETRY, OCULAR; TREATMENT OUTCOME;

EID: 0037183651     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000030935.89559.04     Document Type: Article

References (20)

1. Aldosterone escape during ACE-inhibitor therapy in chronic heart failure
2. The effect of spironolactone on morbidity and mortality in patients with severe congestive heart failure
3. Maximally recommended doses of ACE inhibitors do not completely prevent ACE mediated formation of angiotensin II in chronic heart failure
4. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group Trandolapril Cardiac Evaluation
5. Compared properties of trandolapril, enalapril, and their diacid metabolites
6. Three new long-acting converting enzyme inhibitors: Relationship between plasma converting enzyme activity and pressor response to angiotensin I
7. Drugs that affect the renin-angiotensin system
8. Measurements of serum ACE activity in vitro after administration of enalapril in man cannot reflect inhibition of the enzyme in vivo
9. Within-patient variability of hormone and cytokine concentrations in heart failure
10. Vasoconstriction is determined by interstitial rather than circulating angiotensin II
11. Value of different clinical and biochemical correlates to assess ACE inhibition
12. The 1166 A/C polymorphism of the angiotensin II type I receptor gene does not correlate with the blood pressure response to angiotensin II in patients with CHF
13. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure
14. Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease
15. Aldosterone in congestive heart failure
16. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid volume depletion
17. Plasma aldosterone concentrations are not related to the degree of angiotensin-converting enzyme inhibition in essential hypertensive patients
18. How often are angiotensin Il and aldosterone concentrations raised during chronic ACE inhibitor therapy
19. Neurohormonal and clinical responses to high-versus low-does enalapril therapy in chronic heart failure
20. Failure of aldosterone suppression despite ACE inhibitor administration in chronic heart failure is associated with ACE DD genotype